Search 

Our location in the Alexandria Center for Life Science enables us to combine our expertise with that of world class researchers here in a vibrant scientific environment.

The Roche Translational and Clinical Research Center (TCRC) is part of the Pharma Research and Early Development (pRED) organization, and will serve as the hub for pRED activities in North America, underscoring the center’s importance to pRED and Roche. The TCRC staff is comprised of highly experienced drug developers who are focused on early clinical development of Roche drug candidates. In addition to advancing Roche’s existing portfolio, the TCRC experts will aim to access external innovation by identifying collaborations ranging from very early discovery platforms through advanced stage molecules.

The Roche Translational and Clinical Research Center (TCRC) is part of the Pharma Research and Early Development (pRED) organization, and will serve as the hub for pRED activities in North America, underscoring the center’s importance to pRED and Roche. The TCRC staff is comprised of highly experienced drug developers who are focused on early clinical development of Roche drug candidates. In addition to advancing Roche’s existing portfolio, the TCRC experts will aim to access external innovation by identifying collaborations ranging from very early discovery platforms through advanced stage molecules.

Rockland Technimed Limited is a diagnostic imaging company, committed to the early diagnosis and treatment of ischemic injury, through its patented Oxy-17® metabolic magnetic resonance imaging medium.

International Epidemiologist with wide ranging expertise in chronic and infectious diseases & interdisciplinary collaborations.

Private email:  stanweiss @ verizon.net

Stanley H. Weiss, MD has been on the RBHS (and legacy UMDNJ) faculties since 1987, and currently is Professor (with tenure) of Medicine at the New Jersey Medical School, and Professor of Epidemiology at the Rutgers School of Public Health. 

He graduated from Yale (1974, BA, summa cum laude and Phi Beta Kappa) and Harvard Medical School (1978, MD). He did a residency in Internal Medicine at Montefiore in the Bronx, and fellowships at the National Cancer Institute in Medical Oncology and in Epidemiology. Dr. Weiss is Board Certified in Internal Medicine and in Medical Oncology, and a fellow of the American College of Epidemiology (“FACE”) and the American College of Physicians (“FACP”).   

On November 2nd, 2015, he will be honored by the American Public Health Association with its Wade Hampton Frost Lecture, its top epidemiology research  award. 

His past professional awards include the NJ Public Health Association’s (NJPHA) highest award – the Dennis J. Sullivan Award (2012), the NJPHA Dr. Ezra Mundy Hunt Award (2007), the first recipient of the American Lung Association of NJ’s “CAREforAIRnj Award for Community  Outreach/Action/Advocacy, the “Cancer Liaison Physician Outstanding Performance Award” from the Commission on Cancer of the American College of Surgeons (2010), the Prostate Net’s “In the Know” National Award (2007), the UMDNJ School of Public Health “Faculty Community Service Award”(2007), and the first of the American Society of Clinical Oncology “Travel Awards” for outstanding work (1985). At NJMS, he was elected to membership in Sigma Xi chapter (1992) and as a Faculty member to the Alpha Omega Alpha [ΑΩΑ] Honor Medical Society, Beta Chapter (inducted 2003). For the latter, he has served as an officer as the Assistant Secretary/Treasurer since 2006, and helped to develop its Research Award.

Dr. Weiss’ research focuses on epidemiology, public health, study design and methodology, evaluation, policy issues and interdisciplinary studies and projects.  These have primarily been related to cancer, asthma, retroviruses including HIV/AIDS and HTLV, infectious diseases, methodological and policy issues, and bioethics.  In addition, he is the PI of several community-outreach initiatives (including the implementation and evaluation of structured tool sets for individuals to improve their health) and PI/co-PI of a series of studies concerning asthma with key new understanding of asthma epidemiology as well as policy implications.  He is the PI of a set of prospective cohort studies numbering ~10,000 injection drug users begun in the 1980’s, over 30 years ago, which is linked to personal identifying information and  a biospecimen collection of ~ 100,000 vials.  

Dr. Weiss has authored over 350 published, peer-reviewed medical articles, chapters and abstracts. Among his research accomplishments (as lead or senior author, except as noted):

• First assessment of the prototype HIV screening test.
• Part of the team describing the 2nd case worldwide of HTLV-II infection.
• First demonstration of high infection rates with HTLV-II in drug users.
• First report that among persons seropositive for HIV antibody, adverse outcomes had significant latency, and these steadily mounted over time to high rates of severe disease and death.
• First demonstrated US case (2nd worldwide) of occupational acquisition of HIV in healthcare workers, associated this with HIV needlestick) exposure, and leading to vast changes in the workplace.
• First case of occupational acquisition of HV in research workers.
• First US case of HIV-2 – detected at University Hospital, Newark.
• First demonstration of female to male sexual transmission of HIV.
• Part of the team documenting the 2nd case of female to female HIV transmission.
• Wrote substantial parts of the first NJ State Cancer Plan, and then led much of its statewide implementation.
• First demonstration that the latency from initial asbestos exposure until development of mesothelioma is far longer than has been generally understood.
• First to demonstrate that the US epicenter for HIV infection in injection drug users centered about NYC, and the first to enroll women in an HIV-era cohort study.
• First to assess geographic distribution of asthma in children across an entire state.
• First to discover confirmed very high rates of HCV in IDU’s, presaging the epidemic consequences of HCV (liver failure and hepatocellular carcinoma).
• A member of the team demonstrating immunologic abnormalities associated with HTLV-II, such as spontaneous lymphocyte proliferation and lymphocyte subset changes.

Dr. Weiss is the immediate past Chair of the International Joint Policy Committee of the Societies of Epidemiology (see: www.ijpc-se.org). He has continuously served on the Executive Board of the NJPHA since 1993, through the terms of over a dozen NJPHA presidents, and the founding Chair of its Epidemiology Section. He is a past chair of the Epidemiology Section and past vice-chair of the Science Board of the American Public Health Association. He is a longstanding member of the Coordinating Committee of the Pediatric/Adult Asthma Coalition of NJ and co-chair of its Evaluation Workgroup, and the Community Liaison Physician of the NJMS/University Hospital Oncology Program to the CoC and the vice-chair of its Oncology Committee.  

As the founder and director of the Essex County Cancer Coalition and of its expanded successor, the Essex-Passaic Chronic Disease Coalition (a.k.a. the Essex-Passaic Wellness Coalition; http://web.njms.rutgers.edu/EPWC), he helps implement community-based education, outreach, screening and prevention of cancer and is a public policy advocate.   

His RBHS teaching has focused on evidence-based medicine approaches and critical analysis of medical literature, and the epidemiology and prevention of both chronic and infectious diseases.  He served in 2012-13 as the co-course director of the 2nd year NJMS “Disease Processes, Prevention & Therapeutics” course. He also teaches in the RBHS School of Public Health.  

Other professional affiliations include the NJ Allergy, Asthma & Immunology Society, the NY Allergy and Asthma Society, the American Society of Clinical Oncology, Alpha Omega Alpha (the medical honor society; he is the assistant secretary-treasurer of the Beta Chapter of NJ), the Society for Epidemiologic Research, the International Epidemiological Association, and one of the Founding Members of the Infectious Disease Society of NJ.  He is a past Fellow of the Infectious Diseases Society of America. He’s been in leadership roles for each of the four North American Congresses of Epidemiology.

Our unique technology combines visco elastic shock absorbers with rigid components in one device to restore the anatomical functions. Our first product 

B Dyn relieves pressure on the inter vertebral disc as well as the articular facets and by controlling motion, preserves the intervertebral disc and the articular facets from final fusion. For the patients the outcomes evaluated 2 years after the surgery are superior to the standard technic of fusion.

Lumbar Spine Degenerative Market

Superior clinical outcomes 

engaged in the research, development, manufacturing and marketing of therapeutic solutions focused on patients’ needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme.

Our software enables a rapid development of web or mobile portals or "app stores", dedicated to help people to manage their health or autonomy.

Technically, we facilitate interaction between services, serious games, algorithms and medical contents that will be integrated in a single portal where they will have a single management tool and one single database.

In addition, an administration tool enables to its operator the management of the platform : CMS, enrollment, statistics and connectors.

To date, we expect 1 M€ turnover in 2015, with 6 customers, mainly insurers and state organization like CNAM, the equivalent of NHS, the Regional Health Agency (ARS Ile de France) or City of Paris.

For instance, we have developed an e-health portal for employees. This portal, called "MyPrevention", integrates 12 inter-connected applications : e-health prevention applications, an encyclopedia, information and coaching platforms, ...

The services are provided by 12 different companies.

About this project, our lauching plan, forecasts 50 000 users by the end of October 2015 and 400.000 in 2016.

We have also developped a social network which integrates a serious game, an agenda, a visio conference access, a connection with a services platform.

This project has been designed for the dependant persons of the city of Paris and will be launched and operated by the Welfare Department of the City of Paris.

Even if the French market is still under creation, we strongly believe that market shares must be grabbed now. So far, we have a successful commercial activity and we are strongly confident that we will be in a strong position to address a mass e-health market. 

This market will be driven by the demand expressed by end users who expect more collaboration between insurers, national healthcare operators , pharmaceutical labs,  in order to provide them with integrated care services.

Our strategy is always the same :

- identifying the main actors on a market

- finalizing partnership in order to adress the market behind his brand and his expertise.